<DOC>
	<DOCNO>NCT02241551</DOCNO>
	<brief_summary>This prospective , randomized phase II trial . Patients diagnose borderline resectable pancreatic adenocarcinoma randomly assign one two treatment arm , either mFOLFIRINOX gemcitabine nab-paclitaxel . After three cycle treatment gemcitabine/nab-paclitaxel arm 6 cycle mFOLFIRINOX arm , patient restaged CT scan remain borderline resectable improvement disease They proceed SBRT follow surgical resection .</brief_summary>
	<brief_title>Phase II Neoadjuvant Chemotheraphy ( Gemcitabine Nab-Paclitaxel vs. mFOLFIRINOX ) Sterotatic Body Radiation Therapy Borderline Resectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>All patient must meet follow criterion within 28 day randomization ( unless otherwise indicate ) enrol protocol : Histologically cytologically proven adenocarcinoma pancreas . If patient mixed tumor predominant adenocarcinoma pathology , enrol . Subjects stag accord 2010 American Joint Committee Cancer ( AJCC ) stag system pathologic stage T14 , N0 eligible ; primary tumor pancreas ( either pancreatic head , neck , uncinate process , body/tail ) The tumor must deem borderline resectable . Final CT confirmation surgical staging/ eligibility discretion pancreatic surgeon patient . Disease confine locoregional site confirm CT / diagnostic stag laparoscopy avoid occult peritoneal deposit . Diagnostic laproscopy absolutely require Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST v1.1 ) image study CT Screening Endoscopic ultrasound do prior consent within 6 week expect randomization date may use . Karnofsky performance status great equal 70 Eastern Cooperative Oncology Group ( ECOG ) performance 02 . Age &gt; 18 Estimated life expectance &gt; 12 week If female patient child bear potential , must negative serum pregnancy test ( βhCG ) document 72hrs prior administration first study drug Patient screen blood work perform include follow ( draw ≤ 14 day prior randomization ) absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L Platelet count ≥ 100000/mm3 Hemoglobin ( HgB ) ≥ 9g/dL aspartate aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) ≤ 2.5 x upper limit normal ( ULN ) Total Bilirubin ≤ ULN Serum Cr within normal limit ( WNL ) Coagulation study Prothrombin Time International Normalized Ratio ( PT/INR ) partial thromboplastin time ( PTT ) within normal limit ( ±15 % ) . • Patient urinalysis obtain ( ≤14 day prior randomization ) result deem clinically significant investigator . Patient evidence jaundice time enrolment . If stent require alleviate jaundice , metallic . If patient previously place stent plastic , change metallic . Patient 's pain symptom remain stable adjustment analgesic within 7 day prior randomization . Patient must able swallow entreat medication requirement feed tube . Patient 's must intractable nausea vomit prohibits patient oral medication Diabetes must control prior enrollment Disease must encompass reasonable SBRT `` portal '' define treat radiation oncologist Ineligible Histology include nonadenocarcinomas , adenosquamous carcinoma , islet cell carcinoma , cystadenomas , cystadenocarcinomas , carcinoid tumor , duodenal carcinoma , distal bile duct ampullary carcinoma Evidence distant metastasis upright chest xray , CT stag study Subjects recurrent disease Prior radiation therapy upper abdomen liver discretion treat radiation oncologist could impair delivery prescribed radiation treatment Prior chemotherapy Subjects reproductive age breast feed positive pregnancy test Any comorbid condition sufficient severity limit full compliance protocol per assessment individual treating physician Concurrent active infection Previous current malignancy histology within last 3 yrs prior randomization ; exception cervical cancer situ , adequately treat basal cell squamous cell carcinoma skin treat low risk prostate cancer Patient know historical active infection HIV , Hepatitis B Hepatitis C Patient undergone recent major surgery , diagnostic surgical procedure within 4 week prior randomization . Patient history allergy hypersensitivity study drug . Patients history interstitial lung disease , history slowly progressive dyspnea unproductive cough , sarcoidosis , silicosis , interstitial pulmonary fibrosis , pulmonary hypersensitivity pneumonitis multiple allergy Patients great 2 screen peripheral neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Borderline</keyword>
	<keyword>Resectable</keyword>
	<keyword>Pancreatic</keyword>
	<keyword>Cancer</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Chemotheraphy</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Nab-Paclitaxel</keyword>
	<keyword>mFOFIRINOX</keyword>
	<keyword>Sterotatic Body Radiation Therapy</keyword>
</DOC>